Skip to Content
Merck
CN

EHU095931

MISSION® esiRNA

targeting human NHEJ1

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

NACRES:
NA.51
UNSPSC Code:
41105324

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

description

Powered by Eupheria Biotech

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

CCCAACATTTGATTCGTCCTCTGATGGGCATGAGTCTGGCATTACAGTGCCAAGTGAGGGAGCTAGCAACGTTACTTCATATGAAAGACCTAGAGATCCAAGACTACCAGGAGAGTGGGGCTACGCTGATTCGAGATCGATTGAAGACAGAACCATTTGAAGAAAATTCCTTCTTGGAACAATTTATGATAGAGAAACTGCCAGAGGCATGCAGCATTGGTGATGGAAAGCCCTTTGTCATGAATCTGCAGGATCTGTATATGGCAGTCACCACACAAGAGGTCCAAGTGGGACAGAAGCATCA

Ensembl | human accession no.

ENSG00000187736

NCBI accession no.

NM_024782

shipped in

ambient

storage temp.

−20°C

Quality Level

100

General description

MISSION esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class

10 - Combustible liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
VDV
ACIU
QCS
JRR

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ryan Robb et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 25(15), 4749-4760 (2019-05-18)
Activating BRAF mutations, most commonly BRAFV600E, are a major oncogenic driver of many cancers. We explored whether BRAFV600E promotes radiation resistance and whether selectively targeting BRAFV600E with a BRAF inhibitor (vemurafenib, BRAFi) sensitizes BRAFV600E thyroid cancer cells to radiotherapy. Immunoblotting

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service